ReNeuron Group plc Posting of AR & Accounts & Notice of AGM (0688W)
15 Août 2022 - 4:25PM
UK Regulatory
TIDMRENE
RNS Number : 0688W
ReNeuron Group plc
15 August 2022
ReNeuron Group plc
("ReNeuron" or the "Company")
Posting of Annual Report & Accounts
& Notice of AGM
ReNeuron Group plc (AIM: RENE), a UK-based stem cell leader in
stem cell derived exosome technologies, announces that its Annual
Report and Accounts for the year ended 31 March 2022 and the Notice
of the 2022 Annual General Meeting ("AGM") have today been sent to
shareholders and are also available on the Company's website at
www.reneuron.com .
ReNeuron's AGM will be held at 09.30am on Friday 9 September
2022 at the offices of Covington and Burling LLP, Level 54, 22
Bishopsgate, London, EC2N 4BQ
At the time of publication of the notice of AGM, the Government
has lifted most legal restrictions relating to public gatherings
that had previously been in place due to the ongoing COVID-19
Pandemic. In line with this, the Board welcomes the opportunity to
invite shareholders to attend the AGM in person Should this
situation change, shareholders will be notified though our website
www.reneuron.com and, where appropriate by RNS. Attendees will need
to pre-register, please refer to the Notice of AGM or to your proxy
card for information on how to do so.
Shareholders are encouraged to send any questions for the
Chairman to info@reneuron.com at least 48 hours prior to the
meeting. Where appropriate, such questions and answers will be
collated and later published, together with full voting details, in
the Investor Centre of the Company's website at www.reneuron.com
.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Financial Officer
Liberum Capital Limited (NOMAD and
Joint Broker)
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking) +44 (0)20 3110 2000
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Alice Woodings +44 (0)7407 804 654
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived
exosome technologies, harnessing its unique stem cell technologies
to develop 'off the shelf' treatments for diseases with significant
unmet needs.
ReNeuron's stem cell derived proprietary exosome technology
platform offers a delivery mechanism for a variety of payloads such
as siRNA, mRNA, proteins, small molecules and genes. The Group has
a growing number of partner collaborations with Global Pharma,
Biotech and academic partners in this fast-expanding area of
scientific and commercial interest. ReNeuron also has the ability,
through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
The Group has out-licenced its CTX Programme for stroke
disability and hRPC programme in retinitis pigmentosa to Fosun in
China and is looking to out-license both of these programmes in
other territories.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAGPUMGRUPPGCA
(END) Dow Jones Newswires
August 15, 2022 10:25 ET (14:25 GMT)
Reneuron (AQSE:RENE.GB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Reneuron (AQSE:RENE.GB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024